WCN26-6482 EXTENDED USE OF MYCOPHENOLATE MOFETIL IMPROVES REMISSION RATES IN C3GN ALBEIT CONCERNS OF INFECTION EPISODES AND DISEASE PROGRESSION

Read full text Summarise with VIRAT
Authors: Namrata Sarvepalli Rao, Vinay Sagar, Kiran Preet Malhotra, Abhilash Chandra
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

C3 glomerulonephritis (C3GN) belongs to a rare group of disorders with complement pathway dysregulation. While complement factor inhibitors are currently undergoing trials, steroids and mycophenolate mofetil (MMF/Std) are the mainstay of treatment over the last decade. Though the guideline from Kidney Disease: Improving Global Outcomes suggesting a course of MMF/Std for six months, the evidence for the duration of immunosuppression and withdrawing MMF in patients who do not achieve remission is yet unclear.

Fields of Study & Subjects

Complement system in diseases Renal Diseases and Glomerulopathies Vasculitis and related conditions

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106266–106266
Publication date
25 March 2026
Language
EN